Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
Recorded changes
83,427 on record
Recorded policy changes, newest first| Recorded | Payer | Policy | Change |
|---|
| Aug 2, 2026 | Independence Blue Cross | Genetic Testing for Inherited Breast Cancer 1 (BRCA1) and Breast Cancer 2 (BRCA2) Mutations (Independence Administrators)PayerPolicy · IBX-COMMERCIAL-06-02-06 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Genetic Testing for Congenital Long QT Syndrome (Independence Administrators)PayerPolicy · IBX-COMMERCIAL-06-02-31 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Genetic Testing (Independence Administrators)PayerPolicy · IBX-COMMERCIAL-06-02-35AO-99F361E037 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Gender-Affirming InterventionsPayerPolicy · IBX-COMMERCIAL-11-09-02 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Gastric Electrical Stimulation (Enterra), Gastric PacingPayerPolicy · IBX-COMMERCIAL-11-03-15 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Full-Body Monoplace or Multiplace Chamber Hyperbaric Oxygen TherapyPayerPolicy · IBX-COMMERCIAL-07-00-03 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Full-Body Computerized Tomography (CT) Scan ScreeningPayerPolicy · IBX-COMMERCIAL-09-00-24 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Frenectomy, Frenotomy, or Frenoplasty for Ankyloglossia (Tongue-Tie)PayerPolicy · IBX-COMMERCIAL-11-03-05 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Foot Orthotics and Other Podiatric AppliancesPayerPolicy · IBX-COMMERCIAL-05-00-35 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | First-Trimester Prenatal Screening for Fetal Aneuploidy Using Fetal Ultrasound MarkersPayerPolicy · IBX-COMMERCIAL-09-00-36 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Filgrastim (Neupogen) and Related Biosimilars, and tbo-filgrastim (Granix)PayerPolicy · IBX-COMMERCIAL-08-01-73 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Fidanacogene elaparvovec-dzkt (Beqvez)PayerPolicy · IBX-COMMERCIAL-08-02-25 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Fetal SurgeryPayerPolicy · IBX-COMMERCIAL-11-00-03 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Fecal Microbiota Transplantation (FMT)PayerPolicy · IBX-COMMERCIAL-07-05-08 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Fam-trastuzumab deruxtecan-nxki (Enhertu)PayerPolicy · IBX-COMMERCIAL-08-00-12 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Facility Reporting of Observation ServicesPayerPolicy · IBX-COMMERCIAL-00-01-19 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Eye Prostheses and Scleral Cover ShellPayerPolicy · IBX-COMMERCIAL-05-00-83 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Extraction of Bony Impacted Teeth and Exposure of Impacted TeethPayerPolicy · IBX-COMMERCIAL-04-00-05 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Extracorporeal Shock Wave Therapy (ESWT) for Musculoskeletal ConditionsPayerPolicy · IBX-COMMERCIAL-11-14-13 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Experimental/Investigational ServicesPayerPolicy · IBX-COMMERCIAL-12-01-01BU-BC29B59C40 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Exon Skipping Drugs for Duchenne Muscular Dystrophy (DMD) (Eteplirsen (Exondys 51), Golodirsen (Vyondys 53), Viltolarsen (Viltepso), Casimersen (Amondys 45))PayerPolicy · IBX-COMMERCIAL-08-01-34 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Evinacumab-dgnb (Evkeeza)PayerPolicy · IBX-COMMERCIAL-08-01-76 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | eviCore Lab Management (Independence)PayerPolicy · IBX-COMMERCIAL-06-02-52AN-536913BE57 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Evaluation and Treatment of Erectile Dysfunction (ED)PayerPolicy · IBX-COMMERCIAL-11-11-01 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Etranacogene dezaparvovec-drlb (Hemgenix)PayerPolicy · IBX-COMMERCIAL-08-02-03 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Esophagogastroduodenoscopy (EGD) and Endoscopic Retrograde Cholangiopancreatography (ERCP)PayerPolicy · IBX-COMMERCIAL-07-02-22 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Erythropoiesis-Stimulating Agents (ESAs)PayerPolicy · IBX-COMMERCIAL-08-00-75 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Equipment, Supplies, and Pharmaceuticals for the Treatment of DiabetesPayerPolicy · IBX-COMMERCIAL-05-00-05 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Eptinezumab-jjmr (VYEPTI)PayerPolicy · IBX-COMMERCIAL-08-00-45 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Epidural, Paravertebral Facet, and Sacroiliac Joint Injections for Spinal Pain Management (Independence Administrators)PayerPolicy · IBX-COMMERCIAL-11-15-23 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Epcoritamab-bysp (EPKINLY)PayerPolicy · IBX-COMMERCIAL-08-02-12 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Enzyme Replacement Therapy for Mucopolysaccharidosis (e.g., Aldurazyme, Elaprase, Vimizim, Naglazyme, Mepsevii, etc.)PayerPolicy · IBX-COMMERCIAL-08-00-70 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Enzyme Replacement Therapy for Adenosine Deaminase Severe Combined Immune Deficiency (e.g., elapegademase-lvlr [Revcovi])PayerPolicy · IBX-COMMERCIAL-08-01-26 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Enzyme Replacement for the Treatment of Gaucher's DiseasePayerPolicy · IBX-COMMERCIAL-08-00-51 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Enfortumab vedotin-ejfv (Padcev)PayerPolicy · IBX-COMMERCIAL-08-00-43 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Endovascular Stent Graft Repair of Thoracic Aortic Aneurysms and Nonaneurysmal LesionsPayerPolicy · IBX-COMMERCIAL-11-02-17 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Endovascular Grafts for Abdominal Aortic Aneurysms (AAA), Aorto-Iliac Aneurysms, and Infrarenal Aortic AneurysmsPayerPolicy · IBX-COMMERCIAL-11-02-10 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Endoscopic Submucosal Dissection (ESD)PayerPolicy · IBX-COMMERCIAL-11-03-18 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Endometrial AblationPayerPolicy · IBX-COMMERCIAL-11-06-05 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Emapalumab-lzsg (Gamifant)PayerPolicy · IBX-COMMERCIAL-08-01-54 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Elranatamab-bcmm (Elrexfio)PayerPolicy · IBX-COMMERCIAL-08-02-18 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Elivaldogene Autotemcel [eli-cel (Skysona)]PayerPolicy · IBX-COMMERCIAL-08-01-92 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Electromyography (EMG) Studies, Nerve Conduction Studies (NCS), and Related Electrodiagnostic StudiesPayerPolicy · IBX-COMMERCIAL-07-03-09 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Electroconvulsive Therapy (ECT)PayerPolicy · IBX-COMMERCIAL-14-00-01 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Elective AbortionPayerPolicy · IBX-COMMERCIAL-11-06-02 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Eladocagene exuparvovec-tneq (Kebilidi)PayerPolicy · IBX-COMMERCIAL-08-02-37 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Efgartigimod alfa - fcab (Vyvgart)PayerPolicy · IBX-COMMERCIAL-08-01-84 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Efbemalenograstim alfa-vuxw (Ryzneuta), Eflapegrastim-xnst (Rolvedon), Pegfilgrastim (Neulasta) and Related BiosimilarsPayerPolicy · IBX-COMMERCIAL-08-01-32 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Eculizumab (Soliris) and Related Biosimilars, Ravulizumab-cwvz (Ultomiris) for intravenous administrationPayerPolicy · IBX-COMMERCIAL-08-00-84 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Durvalumab (Imfinzi) and Tremelimumab-actl (Imjudo)PayerPolicy · IBX-COMMERCIAL-08-01-65 | New policy |
|---|